ticlopidine has been researched along with Prosthesis Durability in 35 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 9.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 7.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| " The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 7.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
| " On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 5.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 3.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| " The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 3.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
| "Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization." | 2.79 | Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014) |
| "Warfarin treatment was an independent predictor of both primary endpoint (OR 1." | 1.34 | Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. ( Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A, 2007) |
| "Intimal hyperplasia is one of the main risk factors for the patency of small diameter bypass grafts." | 1.29 | [Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results]. ( Baccini, P; Baiardi, A; Cariati, P; Ceppa, P; Civalleri, D; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 15 (42.86) | 29.6817 |
| 2010's | 18 (51.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almalla, M | 1 |
| Schröder, J | 1 |
| Hennings, V | 1 |
| Marx, N | 1 |
| Hoffmann, R | 1 |
| Park, J | 1 |
| Shin, DH | 1 |
| Kim, BK | 1 |
| Her, AY | 1 |
| Kim, YH | 2 |
| Choi, HH | 1 |
| Kim, JS | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 1 |
| Hong, MK | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Silber, S | 1 |
| Kirtane, AJ | 1 |
| Belardi, JA | 1 |
| Liu, M | 1 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Windecker, S | 2 |
| Camenzind, E | 1 |
| Boersma, E | 1 |
| Wijns, W | 1 |
| Mauri, L | 1 |
| Rademaker-Havinga, T | 1 |
| Ordoubadi, FF | 1 |
| Suttorp, MJ | 1 |
| Al Kurdi, M | 1 |
| Steg, PG | 1 |
| Loh, JP | 1 |
| Torguson, R | 1 |
| Pendyala, LK | 1 |
| Omar, A | 1 |
| Chen, F | 1 |
| Satler, LF | 1 |
| Pichard, AD | 1 |
| Waksman, R | 1 |
| Guo, B | 1 |
| Tan, Q | 1 |
| Guo, D | 1 |
| Shi, Z | 1 |
| Zhang, C | 1 |
| Guo, W | 1 |
| Park, SH | 1 |
| Rha, SW | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Oh, DJ | 1 |
| Cho, YH | 1 |
| Choi, WG | 1 |
| Lee, SJ | 1 |
| Choi, SH | 1 |
| Kim, WH | 1 |
| Kim, KC | 1 |
| Cho, JH | 1 |
| Kim, JH | 1 |
| Kim, SM | 1 |
| Bae, JH | 1 |
| Bong, JM | 1 |
| Kang, WY | 1 |
| Baek, JY | 1 |
| Seo, JB | 1 |
| Chung, WY | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Suh, J | 1 |
| Kim, MW | 1 |
| Kim, YJ | 1 |
| Choi, HJ | 1 |
| Soh, JW | 1 |
| Jeger, RV | 1 |
| Pfisterer, ME | 1 |
| Sørensen, R | 1 |
| von Felten, S | 1 |
| Alber, H | 1 |
| Bonetti, PO | 1 |
| Eberli, F | 1 |
| Erne, P | 1 |
| Pedrazzini, G | 1 |
| Rickli, H | 1 |
| Galatius, S | 1 |
| Kaiser, CA | 1 |
| Schulz-Schüpke, S | 1 |
| Byrne, RA | 1 |
| Ten Berg, JM | 1 |
| Neumann, FJ | 3 |
| Han, Y | 1 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 1 |
| Maeng, M | 1 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Mudra, H | 1 |
| von Hodenberg, E | 1 |
| Wöhrle, J | 1 |
| Angiolillo, DJ | 2 |
| von Merzljak, B | 1 |
| Rifatov, N | 1 |
| Kufner, S | 1 |
| Morath, T | 1 |
| Feuchtenberger, A | 1 |
| Ibrahim, T | 1 |
| Janssen, PW | 1 |
| Valina, C | 1 |
| Li, Y | 1 |
| Desmet, W | 1 |
| Abdel-Wahab, M | 1 |
| Tiroch, K | 1 |
| Hengstenberg, C | 1 |
| Bernlochner, I | 1 |
| Fischer, M | 1 |
| Schunkert, H | 1 |
| Laugwitz, KL | 1 |
| Schömig, A | 2 |
| Mehilli, J | 1 |
| Kastrati, A | 2 |
| Schoechlin, S | 1 |
| Ruile, P | 1 |
| Pache, G | 1 |
| Ghodsizad, A | 1 |
| Badiye, A | 1 |
| Zeriouh, M | 1 |
| Pae, W | 1 |
| Koerner, MM | 1 |
| Loebe, M | 1 |
| Barthwal, R | 1 |
| Herman, BA | 1 |
| Conroy, MM | 1 |
| Bolsin, SN | 1 |
| Pattullo, SJ | 1 |
| Jayasinghe, R | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Gaborit, B | 1 |
| Castelli, C | 1 |
| Poyet, R | 1 |
| Bali, L | 1 |
| Morange, PE | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Giannini, C | 1 |
| De Carlo, M | 2 |
| Guarracino, F | 1 |
| Donne, MG | 1 |
| Benedetti, G | 1 |
| Verunelli, F | 1 |
| Petronio, AS | 2 |
| Hochholzer, W | 1 |
| Trenk, D | 1 |
| Fromm, MF | 1 |
| Valina, CM | 1 |
| Stratz, C | 1 |
| Bestehorn, HP | 1 |
| Büttner, HJ | 1 |
| Barison, A | 1 |
| Bellini, F | 1 |
| Capozza, PF | 1 |
| Lunardini, A | 1 |
| Varenhorst, C | 1 |
| Koul, S | 1 |
| Erlinge, D | 1 |
| Lagerqvist, B | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| James, S | 1 |
| Linnemann, B | 1 |
| Thalhammer, A | 1 |
| Wolf, Z | 1 |
| Tirneci, V | 1 |
| Vogl, TJ | 1 |
| Edelgard Lindhoff-Last, A | 1 |
| Charlot, M | 1 |
| Nielsen, LH | 1 |
| Lindhardsen, J | 1 |
| Ahlehoff, O | 1 |
| Olsen, AM | 1 |
| Hansen, ML | 1 |
| Hansen, PR | 1 |
| Madsen, JK | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Strecker, EP | 1 |
| Boos, IB | 1 |
| Göttmann, D | 1 |
| Vetter, S | 1 |
| von Mach, MA | 1 |
| Eich, A | 1 |
| Weilemann, LS | 1 |
| Münzel, T | 1 |
| Karvouni, E | 1 |
| Korovesis, S | 1 |
| Katritsis, DG | 1 |
| Vats, HS | 1 |
| Hocking, WG | 1 |
| Rezkalla, SH | 1 |
| Gershlick, AH | 1 |
| Richardson, G | 1 |
| Wiper, AJ | 1 |
| Roberts, DH | 1 |
| Wenaweser, P | 1 |
| Billinger, M | 1 |
| Cook, S | 1 |
| Togni, M | 1 |
| Meier, B | 1 |
| Haeberli, A | 1 |
| Hess, OM | 1 |
| Karjalainen, PP | 1 |
| Porela, P | 1 |
| Ylitalo, A | 1 |
| Vikman, S | 1 |
| Nyman, K | 1 |
| Vaittinen, MA | 1 |
| Airaksinen, TJ | 1 |
| Niemelä, M | 1 |
| Vahlberg, T | 1 |
| Airaksinen, KE | 1 |
| Jiménez-Quevedo, P | 1 |
| Sabaté, M | 1 |
| Alfonso, F | 1 |
| Hernández-Antolín, R | 1 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Bañuelos, C | 1 |
| Escaned, J | 1 |
| Moreno, R | 1 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Macaya, C | 1 |
| Simoni, G | 1 |
| Galleano, R | 1 |
| Ceppa, P | 1 |
| Desalvo, P | 1 |
| Cariati, P | 1 |
| Baccini, P | 1 |
| Lenti, E | 1 |
| Baiardi, A | 1 |
| Civalleri, D | 1 |
| Oemrawsingh, PV | 1 |
| Schalij, MJ | 1 |
| Udayachalerm, W | 1 |
| van der Wall, EE | 1 |
| Bruschke, AV | 1 |
| Shin, EK | 1 |
| Son, JW | 1 |
| Sohn, MS | 1 |
| Jin, DK | 1 |
| Park, GS | 1 |
| Koh, KK | 1 |
| Ahn, TH | 1 |
| Choi, IS | 1 |
| Schühlen, H | 1 |
| Pache, J | 1 |
| Dirschinger, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803] | 0 participants (Actual) | Interventional | 2013-01-31 | Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.) | |||
| Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206] | Phase 4 | 4,005 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement[NCT00457236] | 800 participants | Observational | 2003-03-31 | Active, not recruiting | |||
| Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| E-ZES | 61 |
| C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
| C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
| E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
1 review available for ticlopidine and Prosthesis Durability
| Article | Year |
|---|---|
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
8 trials available for ticlopidine and Prosthesis Durability
| Article | Year |
|---|---|
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug- | 2015 |
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Confidence | 2010 |
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co | 2011 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
26 other studies available for ticlopidine and Prosthesis Durability
| Article | Year |
|---|---|
Long-term outcome after angiographically proven coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E | 2013 |
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co | 2013 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2014 |
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Topics: Aged; Alleles; Angiography, Digital Subtraction; Ankle Brachial Index; Arteriosclerosis Obliterans; | 2014 |
Early hypoattenuated leaflet thickening and restricted leaflet motion of a Lotus transcatheter heart valve detected by 4D computed tomography angiography.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Clopidogrel; Coronary Angiography; Female; | 2015 |
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat | 2016 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studi | 2008 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate | 2009 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate | 2009 |
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins | 2009 |
Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Clopidogrel; Combined M | 2013 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Bicycling; Clopidogrel; Constriction, Pathologic; Dr | 2012 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf | 2012 |
Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Anticoagula | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary | 2006 |
Drug eluting stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Implants; Humans; Platelet Ag | 2006 |
Stent thrombosis: consider also low response to antiplatelets.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr | 2007 |
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel; | 2007 |
[Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results].
Topics: Animals; Anticoagulants; Blood Vessel Prosthesis; Disease Models, Animal; Drug Evaluation, Preclinic | 1995 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor | 2001 |
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
Topics: Aged; Coronary Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregati | 2001 |